KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBIT Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of EBIT Margin data on record, last reported at 6.12% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 1502.0% year-over-year to 6.12%; the TTM value through Dec 2025 reached 9.78%, up 412.0%, while the annual FY2025 figure was 9.78%, 412.0% up from the prior year.
  • EBIT Margin reached 6.12% in Q4 2025 per ACAD's latest filing, down from 12.83% in the prior quarter.
  • Across five years, EBIT Margin topped out at 97.23% in Q4 2022 and bottomed at 97.88% in Q1 2022.
  • Average EBIT Margin over 5 years is 2.89%, with a median of 3.98% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 12479bps in 2021, then crashed -5498bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 69.29% in 2021, then skyrocketed by 40bps to 97.23% in 2022, then crashed by -57bps to 42.25% in 2023, then tumbled by -121bps to 8.9% in 2024, then surged by 169bps to 6.12% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 6.12% in Q4 2025, 12.83% in Q3 2025, and 12.24% in Q2 2025.